Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720876 | 0.90 | PDE4A (0.41) | MDM2 | |
| SCHEMBL1720271 | 0.89 | IDH1 (0.40) | IDH1PIK3CDABL1MERTK | |
| SCHEMBL1720164 | 0.86 | KDM5A (0.42) | IDH1AURKATPX2KDM5AKDM2B | |
| SCHEMBL1720076 | 0.86 | ABL1 (0.42) | IDH1ABL1 | |
| SCHEMBL1719856 | 0.85 | CYP11B2 (0.47) | ABL1 | |
| SCHEMBL1720034 | 0.85 | IDH1 (0.42) | IDH1KDM5AKDM2BKDM4CKDM5B | |
| SCHEMBL1719247 | 0.84 | CYP11B2 (0.46) | ABL1 | |
| SCHEMBL1719251 | 0.84 | CYP11B2 (0.46) | ABL1 | |
| SCHEMBL1724292 | 0.84 | MCHR1 (0.38) | PIK3CD | |
| SCHEMBL15075656 | 0.82 | DAGLB (0.41) | IDH1DAGLBDAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687844-B | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-13 | — | — | CN | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2173735-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687844-A | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2009003861-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | IDH1 1715/4885AURKA 2835/4885TPX2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.